These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 39166457)

  • 1. Predicting tumor mutation burden and VHL mutation from renal cancer pathology slides with self-supervised deep learning.
    Zheng Q; Wang X; Yang R; Fan J; Yuan J; Liu X; Wang L; Xiao Z; Chen Z
    Cancer Med; 2024 Aug; 13(16):e70112. PubMed ID: 39166457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease.
    Gattolliat CH; Couvé S; Meurice G; Oréar C; Droin N; Chiquet M; Ferlicot S; Verkarre V; Vasiliu V; Molinié V; Méjean A; Dessen P; Giraud S; Bressac-De-Paillerets B; Gardie B; Tean Teh B; Richard S; Gad S
    Int J Oncol; 2018 Oct; 53(4):1455-1468. PubMed ID: 30066860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation of clear cell and non-clear cell renal cell carcinomas by all-relevant radiomics features from multiphase CT: a VHL mutation perspective.
    Li ZC; Zhai G; Zhang J; Wang Z; Liu G; Wu GY; Liang D; Zheng H
    Eur Radiol; 2019 Aug; 29(8):3996-4007. PubMed ID: 30523454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status.
    Messai Y; Gad S; Noman MZ; Le Teuff G; Couve S; Janji B; Kammerer SF; Rioux-Leclerc N; Hasmim M; Ferlicot S; Baud V; Mejean A; Mole DR; Richard S; Eggermont AM; Albiges L; Mami-Chouaib F; Escudier B; Chouaib S
    Eur Urol; 2016 Oct; 70(4):623-632. PubMed ID: 26707870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unique molecular alteration patterns in von Hippel-Lindau (VHL) gene in a cohort of sporadic renal cell carcinoma patients from Pakistan.
    Khaliq S; Ajaz S; Firasat S; Shahid S; Hasan AS; Sultan G; Mohsin R; Hashmi A; Mubarak M; Naqvi SA; Rizvi SA; Mehdi SQ; Abid A
    Mutat Res; 2014; 763-764():45-52. PubMed ID: 24727139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal cell tumors with clear cell histology and intact VHL and chromosome 3p: a histological review of tumors from the Cancer Genome Atlas database.
    Favazza L; Chitale DA; Barod R; Rogers CG; Kalyana-Sundaram S; Palanisamy N; Gupta NS; Williamson SR
    Mod Pathol; 2017 Nov; 30(11):1603-1612. PubMed ID: 28731045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VHL and HIF-1α: gene variations and prognosis in early-stage clear cell renal cell carcinoma.
    Lessi F; Mazzanti CM; Tomei S; Di Cristofano C; Minervini A; Menicagli M; Apollo A; Masieri L; Collecchi P; Minervini R; Carini M; Bevilacqua G
    Med Oncol; 2014 Mar; 31(3):840. PubMed ID: 24446253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.
    Nickerson ML; Jaeger E; Shi Y; Durocher JA; Mahurkar S; Zaridze D; Matveev V; Janout V; Kollarova H; Bencko V; Navratilova M; Szeszenia-Dabrowska N; Mates D; Mukeria A; Holcatova I; Schmidt LS; Toro JR; Karami S; Hung R; Gerard GF; Linehan WM; Merino M; Zbar B; Boffetta P; Brennan P; Rothman N; Chow WH; Waldman FM; Moore LE
    Clin Cancer Res; 2008 Aug; 14(15):4726-34. PubMed ID: 18676741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational profile of primary clear cell renal cell carcinoma predicts recurrence and potential candidacy for adjuvant immune checkpoint inhibition.
    Vlachostergios PJ; Papathanassiou M; Anagnostou M; Thodou E; Tamposis I; Mitrakas L; Zachos I; Koukoulis GK; Samara M; Tzortzis V
    F1000Res; 2023; 12():918. PubMed ID: 38933491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
    Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
    Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.
    Moore LE; Nickerson ML; Brennan P; Toro JR; Jaeger E; Rinsky J; Han SS; Zaridze D; Matveev V; Janout V; Kollarova H; Bencko V; Navratilova M; Szeszenia-Dabrowska N; Mates D; Schmidt LS; Lenz P; Karami S; Linehan WM; Merino M; Chanock S; Boffetta P; Chow WH; Waldman FM; Rothman N
    PLoS Genet; 2011 Oct; 7(10):e1002312. PubMed ID: 22022277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic Alterations of Renal Cell Carcinoma and Clinical Implications in the Chinese Population.
    Zhang S; Wang B; Zhang F; Ye J; Ge L; Ma L
    Med Sci Monit; 2019 Apr; 25():2959-2965. PubMed ID: 31007253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrative radiogenomics analysis for predicting molecular features and survival in clear cell renal cell carcinoma.
    Zeng H; Chen L; Wang M; Luo Y; Huang Y; Ma X
    Aging (Albany NY); 2021 Mar; 13(7):9960-9975. PubMed ID: 33795526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined deletion of Vhl, Trp53 and Kif3a causes cystic and neoplastic renal lesions.
    Guinot A; Lehmann H; Wild PJ; Frew IJ
    J Pathol; 2016 Jul; 239(3):365-73. PubMed ID: 27126173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.
    Sun J; Tang Q; Gao Y; Zhang W; Zhao Z; Yang F; Hu X; Zhang D; Wang Y; Zhang H; Song B; Zhang B; Wang H
    J Exp Clin Cancer Res; 2020 Jun; 39(1):104. PubMed ID: 32513235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis.
    Smits KM; Schouten LJ; van Dijk BA; Hulsbergen-van de Kaa CA; Wouters KA; Oosterwijk E; van Engeland M; van den Brandt PA
    Clin Cancer Res; 2008 Feb; 14(3):782-7. PubMed ID: 18245539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of von Hippel-Lindau gene mutation in circulating cell-free DNA for clear cell renal cell carcinoma.
    Sumiyoshi T; Yamasaki T; Takeda M; Mizuno K; Utsunomiya N; Sakamoto H; Nakamura E; Ogawa O; Akamatsu S
    Cancer Sci; 2021 Aug; 112(8):3363-3374. PubMed ID: 34009695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterizing and predicting ccRCC-causing missense mutations in Von Hippel-Lindau disease.
    Serghini A; Portelli S; Troadec G; Song C; Pan Q; Pires DEV; Ascher DB
    Hum Mol Genet; 2024 Jan; 33(3):224-232. PubMed ID: 37883464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PBRM1 and BAP1 as novel targets for renal cell carcinoma.
    Brugarolas J
    Cancer J; 2013; 19(4):324-32. PubMed ID: 23867514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuberous sclerosis complex protein 1 expression is affected by VHL Gene alterations and HIF-1α production in sporadic clear-cell renal cell carcinoma.
    Damjanovic SS; Ilic BB; Beleslin Cokic BB; Antic JA; Bankovic JZ; Milicevic IT; Rodic GS; Ilic DS; Todorovic VN; Puskas N; Tulic CD
    Exp Mol Pathol; 2016 Dec; 101(3):323-331. PubMed ID: 27845047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.